突触组维-2 疾病变体显示了突触前活跃区域内的空间约束
Natalie J Guzikowski1,2, Elena D Bagatelas1,2, Ok-Ho Shin1,2
1Department of Pharmacology, Vanderbilt University, Nashville, TN 37240-7933.
概括
在synaptobrevin-2 (VAMP2) 中引起疾病的变异通过改变SNARE复合物的功能来破坏神经传递. 这些SNARE病变揭示了突触功能障碍的独特模式,对于理解罕见的神经系统疾病至关重要.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 可溶性N-乙基胺胺敏感因子附着蛋白受体 (SNARE) 蛋白质对于精确的突触传输至关重要.
- 最近的发现将SNARE变异与发育性和性脑病变联系起来,称为SNARE病变.
研究的目的:
- 调查九种致病性synaptobrevin-2 (VAMP2) 变种对SNARE复合体功能的影响.
- 阐明SNARE病变中神经传递缺陷背后的机制.
主要方法:
- 对VAMP2变异的SNARE复合的亲和力,稳定性和形状的分析.
- 对自发神经递质释放的纳米空间组织评估.
- 对诱发释放和RIM支架的变异效应的检查.
主要成果:
- 对VAMP2变体的SNARE复合的亲和力,稳定性和形状存在特定的缺陷.
- 观察到失调的神经传递,包括增强自发释放,与患者症状相关.
- 发现RIM脚手架外形成的变异性SNARE复合体,保留唤起的释放.
结论:
- 引起疾病的VAMP2变异导致特定的SNARE复合体缺陷,导致异质神经传递异常.
- 不同SNAREE之间异常神经传递的共享模式需要SNARE病变的功能分类.
- 研究临床相关的基因操纵提供了对罕见疾病和基本突触生理学的见解.
相关概念视频
Fusion of Secretory Vesicles with the Plasma Membrane
16.5K
Proteins and neurotransmitters in secretory vesicles can be released from a cell upon vesicle docking, priming, and fusion with the plasma membrane. Vesicles are docked and primed in preparation for the quick exocytosis of their contents in response to a stimulus. The fusion process is mainly carried out by a SNAP Receptor or SNARE complex, consisting of synaptobrevin, syntaxin-1, and SNAP-25.
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
16.5K
SNAREs and Membrane Fusion
12.3K
Once a transport vesicle has recognized its target organelle, the vesicular membrane needs to fuse with the target membrane to unload the cargo. Transmembrane proteins called SNAREs present on organelle membranes and their vesicles, mediate vesicle fusion.
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
12.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
804
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
804


